Where does Teva Pharmaceuticals Ireland rank among US patent assignees?

According to USPTO PatentsView (2015–2025 granted utility patents), Teva Pharmaceuticals Ireland ranks #15,688 of 49,997 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.

How many patents does Teva Pharmaceuticals Ireland hold?

Teva Pharmaceuticals Ireland holds 19 US utility patents granted between 2015 and 2022, spanning 3 technology areas.

What is Teva Pharmaceuticals Ireland's Innovation Score?

Teva Pharmaceuticals Ireland has an Innovation Score of 26.1 out of 100 (19th percentile of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).

Is Teva Pharmaceuticals Ireland's patent grant rate increasing or decreasing?

Teva Pharmaceuticals Ireland's recent grant velocity is -81% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.

What does claim depth mean for Teva Pharmaceuticals Ireland's patents?

Teva Pharmaceuticals Ireland's patents average 12.3 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.

How is the Teva Pharmaceuticals Ireland patent data sourced?

All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Teva Pharmaceuticals Ireland

Q: What technology areas does Teva Pharmaceuticals Ireland focus on?

Teva Pharmaceuticals Ireland's top technology area is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor) with 19 patents, ranking #393 of 3,490 assignees active in that subclass. Grants appear in 3 CPC subclasses total.

USPTO PatentsView assignee record - 19 granted patents across 3 technology areas, recorded in grant years 2015–2022. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor).

Compiled by PlainPatent · May 15, 2026

RSS updates for this company

Explore the portfolio See the ranking

The verdict

According to USPTO PatentsView, Teva ranks #15,688 of 49,997 tracked US assignees by granted-patent volume, with 19 patents across 3 technology areas.

#15,688
of 49,997 US assignees by volume: 19th percentile
by Innovation Score (26.1/100): 12.3
avg claims per patent: -81%
grant velocity, last 5 yrs

USPTO PatentsView assignee plate

Corpus R15688 · Foreign Corporation #15,688 · 19 grants

GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-NARROW · INNOV-THIN · CLAIMS-RICH · TYPE-FRNCORP · VEL-DROP · BOOK-FULL

GRANTS-MICRO 19 grants
MID-PACK #15,688/49,997
PHOTO-FINISH Terra CO2 Technology…
CPC-NARROW A61M · 3 areas
INNOV-THIN 26.1/100
CLAIMS-RICH 12.3 claims/avg
TYPE-FRNCORP Foreign Corp
VEL-DROP -81% vel
BOOK-FULL 10/10 fields

Nearest grant-volume peer: Terra CO2 Technology Holdings, Inc. (±0 grants)

Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.

How Teva’s 26.1 Innovation Score adds up

The same four weighted components behind every Innovation Score on PlainPatent: portfolio volume, grant velocity, technology breadth, and claim depth.

Volume 10.3 pts (40%) Velocity 2.2 pts (8%) Breadth 6.1 pts (23%) Claim depth 7.4 pts (28%)

Qualcomm Incorporated · highest

85
Teva Pharmaceuticals… · this assignee

26
3D Lighting… · lowest

7

What this shows Teva's Innovation Score is 26.1/100 (19th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.

Does more volume mean deeper claims for Teva?

Each dot is one of Teva’s 8 nearest volume peers (same corpus rank neighbourhood as the chart above), placed by total granted patents (horizontal) against average claims per patent (vertical). Teva’s own 12.3 claims/patent is at or below the 17.5 median for these volume peers. Volume here does not track with deeper claims; several lower-volume peers claim more thoroughly per patent.

Teva vs its 8 nearest volume peers: granted patents vs average claims per patent. Source: USPTO PatentsView.

Where Teva's grants concentrate

Teva Pharmaceuticals Ireland is a focused PatentsView assignee: 3 CPC subclasses with 100% of grants classified under A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor). Peak complete grant year is 2015 (4 grants) versus a trough of 1 in 2019. By volume, Teva sits between Terra CO2 Technology Holdings, Inc. and The United States of America, as represented by the Secretary of Homeland Security.

Teva's three-year grant acceleration

Teva Pharmaceuticals Ireland shows 1 grants in 2022–2024 against only 3 in 2019–2021. That prior window is too thin for a growth multiple (rename and spin-out assignees look artificially high when the baseline is near zero), so PlainPatent withholds a ranked acceleration claim here.

Terra CO2 Technol…

19
Terravia Holdings

19
Tessera Advanced

19
Testo

19
The Hartford Stea…

19
The Ohio State Un…

19
The Trustees of t…

19
The United States…

19
Teva Pharmaceutic… ◀

19

What this shows Teva holds 19 patents at rank #15,705, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Companies ranked near Teva

By rank, the assignees closest to #15,705 in granted patent volume.

Leaders in A61M (Devices FOR Introducing Media Into)

Other assignees with the most granted patents in Teva's primary technology class.

Teva's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

26 19th percentile higher than 19% of 49,997 US assignees

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

USPTO utility patent grants by year · 2015–2022

Grants by year

Teal-shaded recent years (2020–present) versus the 2015–2019 baseline. Full figures in the table below.

View data table

Teva Pharmaceuticals Ireland patent grants by year, 2015–2025
Year	Patents Granted	Share of Period
2015	4	21.1%
2016	3	15.8%
2017	4	21.1%
2018	4	21.1%
2019	1	5.3%
2020	2	10.5%
2022	1	5.3%

Which technologies does Teva Pharmaceuticals Ireland patent most?

A61M - Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor 19

G06M - Counting MECHANISMS; Counting OF Objects NOT Otherwise Provided FOR 19

Y10T - Technical Subjects Covered BY Former US Classification 19

Top 3 of 3 technology areas

More on this record

Data Source

USPTO PatentsView, US granted patents 2015–2025

View all rankings → How is Innovation Score calculated?

What to do with this data

Teva Pharmaceuticals Ireland's patent record in context - here's where to go next.

Teva Pharmaceuticals Ireland's lead technology class is A61M (Devices FOR Introducing Media Into, OR Onto, THE Body ; Devices FOR Transducing Body Media OR FOR Taking Media From THE Body ; Devices FOR Producing OR Ending Sleep OR Stupor), 100% of its portfolio - see every assignee active in that class. Explore A61M
Ranked #15,688 of 49,997 tracked assignees by patent volume - see the full leaderboard. See the ranking
Compare Teva Pharmaceuticals Ireland against Terra CO2 Technology Holdings, Inc., an assignee filing at a similar volume. Compare portfolios
Innovation Score of 26.1/100 blends volume, velocity, technology breadth, and claim depth. How it's calculated

Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.

Data sourced from USPTO PatentsView - official U.S. government patent data. See our methodology for computation details. Retrieved and formatted by PlainPatent

Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the USPTO PatentsView database. Consult a qualified professional before making decisions based on this data.

Read our methodology - how this data is sourced, computed, and verified.

Data sources used on this page

USPTO PatentsView - the disambiguated bulk patent-grant, assignee, and CPC data this page's figures are derived from. patentsview.org
Cooperative Patent Classification (CPC) - the joint USPTO/EPO classification scheme used to group patents by technology area. cooperativepatentclassification.org
USPTO Patent Public Search - the official interface to verify the status of any individual patent. ppubs.uspto.gov

Compiled by PlainPatent , US Patent Intelligence Editorial Process · May 15, 2026

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.